Percheron raises $2.2 million to back phase II push for HMBD-002

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured $2.2 million through a fully subscribed entitlement offer, ...
Fierce Biotech

Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure

Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of ...
FierceBiotech

AnaptysBio abandons rosnilimab for ulcerative colitis after phase 2 fail

AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis (UC) after the PD-1 agonist flunked a phase 2 study. The San Diego-based biopharma assessed rosnilimab in the midstage study ...

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
ascopubs.org

Randomized phase II study to evaluate treatment with induction therapy with nivolumab plus ipilimumab, followed by nivolumab with chemoradiotherapy versus standard of care with ...

TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of ...